Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib in moderately to severely active ulcerative colitis
NCT02914522Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2016
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 40
01
Overview
Phase 3, randomised, double-blind trial of filgotinib in ulcerative colitis (UC) (9 arms), sponsored by Gilead Sciences. Primary endpoint: Endoscopy/Bleeding/Stool Frequency Remission at 58 weeks. Started Nov 2016; status: completed.
02
Drugs
filgotinib
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02914522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02914522.